Clinical Data on THALOMID(R) and REVLIMID(TM) to be Presented at XXII Chemotherapy Foundation Symposium

Clinical Data on THALOMID(R) and REVLIMID(TM) to be Presented at XXII Chemotherapy Foundation Symposium
Tuesday November 9, 7:30 am ET
Presentations on Clinical Studies Using Thalidomide in Solid Tumors and REVLIMID in Myelodysplastic Syndromes

WARREN, N.J., Nov. 9 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG - News) announced that clinical investigators from leading cancer research centers will present clinical data from ongoing trials of THALOMID (thalidomide) and REVLIMID at the XXII Chemotherapy Foundation Symposium in New York City, New York from November 10-13, 2004.
Full Text: http://biz.yahoo.com/prnews/041109/nytu035_1.html